

# Linwah Yip

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3568245/publications.pdf>

Version: 2024-02-01

119  
papers

7,641  
citations

66234

42  
h-index

53109

85  
g-index

119  
all docs

119  
docs citations

119  
times ranked

5271  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	3.8	775
2	Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3390-3397.	1.8	712
3	Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	0.8	448
4	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer, 2014, 120, 3627-3634.	2.0	445
5	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid, 2015, 25, 1217-1223.	2.4	344
6	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. JAMA Oncology, 2019, 5, 204.	3.4	317
7	The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of Surgery, 2020, 271, e21-e93.	2.1	290
8	Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer, 2018, 124, 1682-1690.	2.0	274
9	Contribution of molecular testing to thyroid fine-needle aspiration cytology of follicular lesion of undetermined significance/atypia of undetermined significance. Cancer Cytopathology, 2010, 118, 17-23.	1.4	229
10	MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma. Annals of Surgical Oncology, 2011, 18, 2035-2041.	0.7	216
11	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
12	Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery, 2009, 146, 1215-1223.	1.0	149
13	RAS Mutations in Thyroid Cancer. Oncologist, 2013, 18, 926-932.	1.9	144
14	A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 2012, 118, 2069-2077.	2.0	139
15	Cost Impact of Molecular Testing for Indeterminate Thyroid Nodule Fine-Needle Aspiration Biopsies. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1905-1912.	1.8	131
16	RAS Mutations in Thyroid FNA Specimens Are Highly Predictive of Predominantly Low-Risk Follicular-Pattern Cancers. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E914-E922.	1.8	128
17	BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer. Annals of Surgical Oncology, 2013, 20, 47-52.	0.7	121
18	Thyroid Nodules (≤4cm): Can Ultrasound and Cytology Reliably Exclude Cancer?. World Journal of Surgery, 2014, 38, 614-621.	0.8	105

#	ARTICLE	IF	CITATIONS
19	Patient Age-associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 438-445.	0.8	102
20	Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer. <i>Annals of Surgery</i> , 2015, 262, 519-525.	2.1	100
21	New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers. <i>Clinical Cancer Research</i> , 2013, 19, 2283-2288.	3.2	84
22	PAX8/PPAR $\gamma$ 3 Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma. <i>Thyroid</i> , 2014, 24, 1369-1374.	2.4	83
23	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3241-3250.	1.8	80
24	BRAF mutation detection in indeterminate thyroid cytology specimens. <i>Cancer Cytopathology</i> , 2013, 121, 197-205.	1.4	71
25	GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. <i>Thyroid</i> , 2019, 29, 161-173.	2.4	69
26	A Clinical Algorithm for Fine-Needle Aspiration Molecular Testing Effectively Guides the Appropriate Extent of Initial Thyroidectomy. <i>Annals of Surgery</i> , 2014, 260, 163-168.	2.1	66
27	Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. <i>Cancer Cytopathology</i> , 2014, 122, 873-882.	1.4	63
28	Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis. <i>Thyroid</i> , 2019, 29, 1237-1243.	2.4	61
29	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <i>Journal of the National Cancer Institute</i> , 2018, 110, 362-370.	3.0	60
30	Both BRAF V600E Mutation and Older Age ( $\geq 65$ Years) are Associated with Recurrent Papillary Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 3566-3571.	0.7	59
31	Outcome and Prognostic Factors After Adrenalectomy for Patients with Distant Adrenal Metastasis. <i>Annals of Surgical Oncology</i> , 2013, 20, 3491-3496.	0.7	59
32	The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer. <i>Oncologist</i> , 2010, 15, 1285-1293.	1.9	58
33	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2787-2795.	0.8	58
34	Preoperative detection of RAS mutation may guide extent of thyroidectomy. <i>Surgery</i> , 2017, 161, 168-175.	1.0	56
35	Benign call rate and molecular test result distribution of ThyroSeq v3. <i>Cancer Cytopathology</i> , 2019, 127, 161-168.	1.4	50
36	The Small Abnormal Parathyroid Gland is Increasingly Common and Heralds Operative Complexity. <i>World Journal of Surgery</i> , 2014, 38, 1274-1281.	0.8	49

#	ARTICLE	IF	CITATIONS
37	The Adrenal Mass: Correlation of Histopathology with Imaging. <i>Annals of Surgical Oncology</i> , 2010, 17, 846-852.	0.7	48
38	Suspicious Ultrasound Characteristics Predict <i>BRAF</i> <sup>V600E</sup> -Positive Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2012, 22, 585-589.	2.4	48
39	Surgeon volume and adequacy of thyroidectomy for differentiated thyroid cancer. <i>Surgery</i> , 2014, 156, 1453-1460.	1.0	47
40	Molecular and Histopathologic Characteristics of Multifocal Papillary Thyroid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1586-1591.	2.1	46
41	The Final Intraoperative Parathyroid Hormone Level: How Low Should It Go?. <i>World Journal of Surgery</i> , 2014, 38, 558-563.	0.8	46
42	Thyroid Nodules ≤4cm: Can Ultrasound and Cytology Reliably Exclude Cancer? Reply. <i>World Journal of Surgery</i> , 2014, 38, 1556-1557.	0.8	46
43	Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. <i>Surgery</i> , 2018, 163, 81-87.	1.0	46
44	<i>BRAF</i> V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. <i>European Journal of Cancer</i> , 2020, 124, 161-169.	1.3	41
45	Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study. <i>Cancer</i> , 2021, 127, 1779-1787.	2.0	38
46	Characterization of thyroid cancer driven by known and novel ALK fusions. <i>Endocrine-Related Cancer</i> , 2019, 26, 803-814.	1.6	38
47	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3228-3238.	1.8	36
48	Molecular-Directed Treatment of Differentiated Thyroid Cancer. <i>JAMA Surgery</i> , 2016, 151, 663.	2.2	35
49	Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. <i>Surgery</i> , 2013, 154, 730-738.	1.0	34
50	Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. <i>Annals of Surgery</i> , 2020, 271, 399-410.	2.1	33
51	Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism. <i>Surgery</i> , 2008, 144, 1002-1007.	1.0	30
52	Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. <i>Journal of Surgical Oncology</i> , 2015, 111, 43-50.	0.8	30
53	The clinical importance of parathyroid atypia: Is long-term surveillance necessary?. <i>Surgery</i> , 2015, 158, 929-936.	1.0	28
54	Can a Lightbulb Sestamibi SPECT Accurately Predict Single-Gland Disease in Sporadic Primary Hyperparathyroidism?. <i>World Journal of Surgery</i> , 2008, 32, 784-792.	0.8	27

#	ARTICLE	IF	CITATIONS
55	Completion thyroidectomy: A risky undertaking?. American Journal of Surgery, 2019, 218, 695-699.	0.9	26
56	Outcomes of Adrenal Venous Sampling in Patients with Bilateral Adrenal Masses and ACTH-Independent Cushing's Syndrome. World Journal of Surgery, 2019, 43, 527-533.	0.8	26
57	Factors associated with late recurrence after parathyroidectomy for primary hyperparathyroidism. Surgery, 2020, 167, 160-165.	1.0	26
58	Summary statement: Utility of molecular marker testing in thyroid cancer. Surgery, 2010, 148, 1313-1315.	1.0	25
59	Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma. Annals of Surgical Oncology, 2017, 24, 3624-3630.	0.7	24
60	The Clinical Utility of Molecular Testing in the Management of Thyroid Follicular Neoplasms (Bethesda IV Nodules). Annals of Surgery, 2020, 272, 621-627.	2.1	23
61	Molecular alterations in Hurthle cell nodules and preoperative cancer risk. Endocrine-Related Cancer, 2021, 28, 301-309.	1.6	23
62	Molecular diagnostic testing and the indeterminate thyroid nodule. Current Opinion in Oncology, 2014, 26, 8-13.	1.1	21
63	Sestamibi SPECT/CT versus SPECT only for preoperative localization in primary hyperparathyroidism: a single institution 8-year analysis. Surgery, 2018, 163, 643-647.	1.0	21
64	Colloid-rich follicular neoplasm/suspicious for follicular neoplasm thyroid fine-needle aspiration specimens: Cytologic, histologic, and molecular basis for considering an alternate view. Cancer Cytopathology, 2013, 121, 718-728.	1.4	20
65	Gasless Transaxillary Endoscopic Thyroidectomy with Robotic Assistance: A High-Volume Experience in North America. Thyroid, 2018, 28, 1655-1661.	2.4	20
66	Sestamibi SPECT Intensity Scoring System in Sporadic Primary Hyperparathyroidism. World Journal of Surgery, 2009, 33, 426-433.	0.8	19
67	Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?. Thyroid, 2021, 31, 1673-1682.	2.4	19
68	Intraoperative Pathologic Examination in the Era of Molecular Testing for Differentiated Thyroid Cancer. Journal of the American College of Surgeons, 2012, 215, 546-554.	0.2	18
69	Loss of heterozygosity of selected tumor suppressor genes in parathyroid carcinoma. Surgery, 2008, 144, 949-955.	1.0	16
70	Clinical Application of Molecular Testing of Fine-needle Aspiration Specimens in Thyroid Nodules. Otolaryngologic Clinics of North America, 2014, 47, 557-571.	0.5	15
71	Comparative characteristics of primary hyperparathyroidism in pediatric and young adult patients. Surgery, 2016, 160, 1008-1016.	1.0	15
72	Clinical and Biochemical Features of Pheochromocytoma Characteristic of Von Hippel-Lindau Syndrome. World Journal of Surgery, 2020, 44, 570-577.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. <i>Scientific Reports</i> , 2020, 10, 8031.	1.6	12
74	A specific enhanced recovery protocol decreases opioid use after thyroid and parathyroid surgery. <i>Surgery</i> , 2021, 169, 197-201.	1.0	12
75	Unique Molecular Signatures Are Associated with Aggressive Histology in Pediatric Differentiated Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 236-244.	2.4	12
76	Decision Making in Indeterminate Thyroid Nodules and the Role of Molecular Testing. <i>Surgical Clinics of North America</i> , 2019, 99, 587-598.	0.5	11
77	Fibromyalgia symptoms and medication requirements respond to parathyroidectomy. <i>Surgery</i> , 2014, 156, 1614-1621.	1.0	10
78	Thyroid Carcinoma: The Surgeon's Perspective. <i>Radiologic Clinics of North America</i> , 2011, 49, 463-471.	0.9	9
79	Adrenal Imaging Features Predict Malignancy Better than Tumor Size. <i>Annals of Surgical Oncology</i> , 2015, 22, 721-727.	0.7	9
80	Immediate laparoscopic adrenalectomy versus observation: cost evaluation for incidental adrenal lesions with atypical imaging characteristics. <i>American Journal of Surgery</i> , 2012, 204, 462-467.	0.9	8
81	Epithelioid Hemangioendothelioma: a Rare Primary Thyroid Tumor with Confirmation of WWTR1 and CAMTA1 Rearrangements. <i>Endocrine Pathology</i> , 2016, 27, 147-152.	5.2	8
82	Retropharyngeal Parathyroid Glands: Important Differences. <i>World Journal of Surgery</i> , 2018, 42, 437-443.	0.8	8
83	Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas. <i>Thyroid</i> , 2019, 29, 1279-1285.	2.4	7
84	A comparative cost-utility analysis of postoperative calcium supplementation strategies used in the current management of hypocalcemia. <i>Surgery</i> , 2020, 167, 137-143.	1.0	6
85	Is routine 24-hour urine calcium measurement useful during the evaluation of primary hyperparathyroidism?. <i>Surgery</i> , 2022, 171, 17-22.	1.0	6
86	Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?. <i>Endocrine-Related Cancer</i> , 2021, 28, 621-630.	1.6	6
87	Changes in frailty after parathyroid and thyroid surgery. <i>Surgery</i> , 2022, 171, 718-724.	1.0	6
88	Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations. <i>Endocrine-Related Cancer</i> , 2022, 29, 467-473.	1.6	6
89	Predicting malignancy in thyroid nodules: Molecular advances. <i>Head and Neck</i> , 2012, 34, 1355-1361.	0.9	5
90	Automatic Detection of Thyroid and Adrenal Incidentals Using Radiology Reports and Deep Learning. <i>Journal of Surgical Research</i> , 2021, 266, 192-200.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Chronic Lymphocytic Thyroiditis and Aggressiveness of Pediatric Differentiated Thyroid Cancer. <i>Laryngoscope</i> , 2022, 132, 1668-1674.	1.1	5
92	How and when is multiglandular disease diagnosed in sporadic primary hyperparathyroidism?. <i>Surgery</i> , 2022, 171, 35-39.	1.0	5
93	Does impotence improve after parathyroidectomy in men with primary hyperparathyroidism?. <i>Surgery</i> , 2016, 159, 204-210.	1.0	4
94	Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism. <i>Thyroid</i> , 2019, 29, 252-257.	2.4	4
95	Comparison of the collection approaches of 2 large thyroid fine-needle aspiration practices reveals differing advantages for cytology and molecular testing adequacy rates. <i>Journal of the American Society of Cytopathology</i> , 2019, 8, 243-249.	0.2	4
96	Intraoperative Parathyroid Hormone Aspiration: Implementation and Technique. <i>VideoEndocrinology</i> , 2016, 3, .	0.1	4
97	Thoughtful Utilization of Molecular Testing in Refining Thyroid Nodule Risk Assessment: Do Not Throw Out the Baby. <i>Thyroid</i> , 2020, 30, 474-475.	2.4	3
98	Novel Findings on SPECT-CT Tc-99 Sestamibi Imaging for Primary Hyperparathyroidism. <i>Journal of Surgical Research</i> , 2020, 252, 216-221.	0.8	3
99	Histologic hypercellularity in a biopsied normal parathyroid gland does not correlate with hyperfunction in primary hyperparathyroidism. <i>Surgery</i> , 2021, 169, 524-527.	1.0	3
100	Use of Molecular Markers for Cytologically Indeterminate Thyroid Nodules to Optimize Surgical Management. <i>Current Surgery Reports</i> , 2014, 2, 1.	0.4	2
101	Systematic screening after Chernobyl: Insights on radiation-induced thyroid cancer. <i>Cancer</i> , 2015, 121, 339-340.	2.0	2
102	Incidental Diagnosis of Parathyroid Lesions by Preoperative Use of Next-Generation Molecular Testing. <i>World Journal of Surgery</i> , 2018, 42, 2840-2845.	0.8	2
103	Mountain Climbing, Motherhood, and Surgical Practice. <i>JAMA Surgery</i> , 2018, 153, 652.	2.2	2
104	OR21-02 Impact of Nodule Size on the Probability of Hurthle Cell Carcinoma and Other Cancers in Thyroid Nodules with Multiple Chromosomal Copy Number Alterations. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	2
105	Response to the Comment on "The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults". <i>Annals of Surgery</i> , 2021, 274, e746-e747.	2.1	2
106	Granular cell tumor of thyroid: a case series with molecular characterization highlighting unique pitfalls. <i>Endocrine</i> , 2022, 76, 395-406.	1.1	2
107	Thyroid nodule evaluation: How much is too much?. <i>Surgery</i> , 2013, 154, 1417-1419.	1.0	1
108	Molecular Testing of Thyroid Nodules: Distinguishing Misuse from Appropriate Use. <i>Annals of Surgical Oncology</i> , 2014, 21, 1768-1769.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Riskâ€Directed Algorithms for Pediatric PTC Patients: Is It Time?. World Journal of Surgery, 2015, 39, 2266-2268.	0.8	1
110	An Evolving Understanding of the Clinical Implications of NIFTP. World Journal of Surgery, 2018, 42, 327-328.	0.8	1
111	Reinventing Yourself Virtually: Fifth Annual Society of Asian Academic Surgeons Virtual Conference. Journal of Surgical Research, 2021, 267, 612-618.	0.8	1
112	Differentiated Thyroid Cancers of Follicular Cell Origin. Cancer Treatment and Research, 2010, 153, 35-56.	0.2	1
113	A novel mutation in the succinate dehydrogenase subunit D gene in siblings with the hereditary paragangliomaâ€pheochromocytoma syndrome. SAGE Open Medical Case Reports, 2014, 2, 2050313X1455352.	0.2	0
114	Nonoperative Management of Bilateral Adrenal Incidentalomas. JAMA Surgery, 2015, 150, 978.	2.2	0
115	Expanding the Options for Patient-Guided Decision Making in Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 76.	3.8	0
116	Remembering the Hippocratic Oath in Surgical Training. JAMA Surgery, 2019, 154, 958.	2.2	0
117	MON-LB79 Do Ultrasound Patterns and Clinical Parameters Modify the Probability of Thyroid Cancer Predicted by Molecular Testing in Thyroid Nodules With Indeterminate Cytology?. Journal of the Endocrine Society, 2020, 4, .	0.1	0
118	The impact of race and ethnicity on thyroid nodules, malignancy risk, and surgical management commentary on â€Comparing the rate and extent of malignancy in surgically excised thyroid nodules across race and ethnicityâ€ American Journal of Surgery, 2021, , .	0.9	0
119	3D Anatomic Adrenal Modeling Aids Preoperative Planning in Cortical-Sparing Adrenalectomy. VideoEndocrinology, 2018, 5, .	0.1	0